Fig. 5: Usurping CD155 and CD73 activities via synNotch activation of iNK cells can nearly halt tumor growth in an orthotopic patient-derived GBM mouse model.
From: synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
A Study timeline of GBM43 tumor-bearing mice treated with or without engineered iNK cells. B-C Bioluminescence imaging of GBM43 WT tumor-bearing mice and measurement of bioluminescence intensity for individual mice throughout the course of the study (n = 5 mice/groups; two-way ANOVA, Tukey’s multiple comparison test). D-E Average bioluminescence intensity and bodyweight measurements of mice measured throughout the course of the study (n = 5 mice/group). F Kaplan–Meier survival plot of PBS, WT iNK or synNotch-engineered iNK-treated tumor-bearing mice (n = 6 mice/group; Mantel-Cox test). Data are presented as mean values +/- SEM. Source data are provided as a Source Data file.
